Navigation Links
Are intravenous treatments safe? New research raises doubts
Date:8/31/2009

German scientists have identified a serious and previously misunderstood contaminant that brings the safety and efficacy of intravenous treatments into question. In a report published in the September 2009 issue of the Journal of Leukocyte Biology (http://www.jleukbio.org), they show how a common intravenous treatment used to boost blood pressure in ailing patients also contains substances called "advanced glycation end products," which trigger inflammation. These substances result from reactions that occur among the various proteins (called "posttranslational modification") within the intravenous fluid after it has been formulated for use. This study directly challenges today's prevalent belief that advanced glycation end products are not contaminants.

"Improving the quality of infusion solutions by accounting for posttranslational modification of proteins could lead to better clinical outcomes for patients, such as those treated solutions containing albumin," said Angelika Bierhaus, senior scientist and co-study author from the University of Heidelberg in Germany.

To make their discovery, Bierhaus and colleagues detected advanced glycation end products in several currently available albumin infusion solutions and injected separate groups of mice with solutions containing both high and low amounts of this substance. The mice receiving the high levels of advanced glycation end products experienced significantly higher inflammation and death rates than the mice receiving solutions with low levels of advanced glycation end products. This suggests that screening infusion solutions for posttranslational protein modifications and then removing the compounds may improve patient outcomes, especially treatments requiring albumin infusions.

"It is always difficult to learn that what was once thought safe might have more risk than previously appreciated, especially when it relates to treatments mea
'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. FDA Clears MDN-CGS(R) Intravenous Insulin Dosing Software
2. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
3. Most Important Factors Driving Usage of Antibiotics in the ICU Setting are Availability in Intravenous Formulation, Activity Against Key Gram Negative Pathogens, Drug Interactions and Bactericidal Activity
4. New form of intravenous iron treats anemia in chronic kidney disease patients on dialysis
5. Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment
6. New Bill Offers Medicare Reimbursement Fix for Intravenous Immune Globulin
7. Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting
8. Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit
9. Drug-free treatments offer hope for older people in pain
10. Updated Brochure on Gynecologic Cancer Treatments Now Available
11. Plastic Surgery 2007: Where Truth Behind Emerging Cosmetic Treatments Meets Amazing Reconstructive Advances
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... The new report “Carbohydrase Market by Applications (Food ... Type (Amylases, Cellulases, and Others), Source (Microorganisms, Animals, ... Forecasts to 2019", by MarketsandMarkets, identifies the driving ... with analysis of trends, opportunities, winning imperatives, and ... forecasted on the basis of major regions such ...
(Date:7/25/2014)... 25, 2014 In today’s technological era, ... and supporting devices. This benefits the organization in various ... cyber attacks which can destroy the confidential information and ... Risk and Compliance (EGRC) manage and protect the enterprise ... can cause loss in dollars to the comp may. ...
(Date:7/25/2014)... NY (PRWEB) July 25, 2014 ... injury law firm with over 25 years of ... stemming from dangerous prescription drugs, announces the launch ... offer information to those who believe they have ... , The site offers valuable information about the ...
(Date:7/25/2014)... The European liquid chromatography reagents report defines ... and forecast of revenue. The liquid chromatography reagents market ... 2013, and is estimated to grow to around $1581.8 ... from 2013 to 2018. , Browse through the TOC ... an idea of the in-depth analysis provided. This also ...
(Date:7/25/2014)... the vast majority of adults finish all of the food ... new study. This is true for adults from ... Cornell University revealed. They noted their findings could help ... make better choices. "If you put it on your ... director of the Cornell Food and Brand Lab, said in ...
Breaking Medicine News(10 mins):Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6Health News:Rottenstein Law Group LLP Announces Launch of Xarelto Injury Website 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Most Adults Are Members of 'Clean Plate Club' 2
... , , Psychiatric Care ... , , OAKLAND, Calif., July 27 ... a complaint against Mohamed El-Sabaawi with the California Medical Board ... a number of state mental health hospitals without a valid ...
... intensive therapy, study shows , MONDAY, July 27 (HealthDay ... taking medications that lower blood pressure and cholesterol, people ... of developing the most serious complications associated with the ... in the July 27 issue of the Archives ...
... , , , NEW ... medical technology company developing a minimally invasive drug delivery platform for the regional ... progress. In addition, the Company reported its financial results for the second ... , , , Screened 40 ...
... , ARLINGTON, Va., July 27 ... to the article in Pediatrics: H. von Rettberg, T. Hannman, U. ... Di(2-Ethylhexyl)Phthalate-Containing Infusion Systems Increases the Risk for Cholestasis, Pediatrics 124(2): 710-716 (August ... - delivery of nutrition intravenously via plastic tubing - is a life-saving ...
... , , , ... cover issues related to the diagnosis and treatment of infertility with ... including the emotional, scientific and financial aspects. Discussions include information about ... use of donor sperm or donor eggs. , , ...
... , , LOS ... Center specializes in cardiothoracic surgery including mitral valve replacement. Fatigue ... In fact, most people brush off these seemingly minor symptoms and ... of the need for mitral valve replacement ...
Cached Medicine News:Health News:Union of American Physicians and Dentists: Court Appointee El-Sabaawi Practicing Medicine Without a License? 2Health News:Tight Management of Type 1 Diabetes Worth the Effort 2Health News:Tight Management of Type 1 Diabetes Worth the Effort 3Health News:Delcath Systems Provides Update on Progress 2Health News:Delcath Systems Provides Update on Progress 3Health News:Delcath Systems Provides Update on Progress 4Health News:Delcath Systems Provides Update on Progress 5Health News:Delcath Systems Provides Update on Progress 6Health News:Delcath Systems Provides Update on Progress 7Health News:ACC Responds to Study Published in Pediatrics About Phthalate and IV Tubing 2Health News:Southern California Surgical Center (heart411.com) Specializes in Mitral Valve Replacement 2
(Date:7/24/2014)... VIEW, Calif. , July 24, 2014  IRIDEX ... it will release its second quarter 2014 financial results ... 2014. In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
(Date:7/24/2014)... 2014 Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... to discuss the Company,s Second Quarter 2014 financial ... earnings conference call and webcastWhen: , July ... chairman, president and chief executive officer ...
(Date:7/24/2014)... N.J., July 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... manufacturing company, announced its financial results for the second quarter ... , Total revenues of $6.5 million in the ... same quarter in 2013 , Total revenues of $13.3 ... increase of 78% over the same period in 2013 ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... New results from the largest multicenter clinical trial for ... the International Society for Heart & Lung Transplantation (ISHLT) ...  Results show clinical benefit for the use of Everolimus ... 721 randomized patients at 67 medical centers spanning 5 ...
... April 14, 2011 Oxford Finance Corporation (Oxford), a ... a $2 million equipment loan with Synta Pharmaceuticals Corp. ... compounds for use in Synta,s ongoing clinical trials in ... "Synta Pharmaceuticals has a diverse drug pipeline, including ...
Cached Medicine Technology:Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 2Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 3Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 4Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp. 2